Transitional cell carcinoma is a cancer that starts in the specialized lining of the urinary tract, called the urothelium. This lining stretches from the kidneys down through the ureters, into the bladder, and to the upper portion of the urethra. About 84% of these cancers occur in the bladder, making it the most common form of bladder cancer. The remaining cases arise in the kidney’s renal pelvis (roughly 9%), the ureter (4%), or the urethra (2.5%).
Where It Starts and Why the Lining Matters
The urothelium is sometimes called “transitional epithelium” because its cells can stretch and change shape as the bladder fills and empties. It’s made up of three to seven layers: basal cells at the bottom, intermediate cells in the middle, and large, flat “umbrella cells” on the surface that act as the waterproof barrier between urine and the body’s tissues. Cancer develops when cells in this lining begin to grow out of control, and because the same type of tissue lines the entire urinary tract, the disease can appear at any point along it.
Risk Factors
Smoking is the single biggest preventable cause. Tobacco use is linked to nearly half of all bladder cancer cases, and current smokers face two to four times the risk of non-smokers. Even former smokers carry about three times the baseline risk, though it decreases over time after quitting.
Occupational exposure to certain industrial chemicals is the other major driver. A group of compounds called aromatic amines, found in dye manufacturing, rubber production, paints, fungicides, and plastics, have been recognized as bladder carcinogens for over a century. One of these compounds also appears in cigarette smoke, which partly explains why smoking is so strongly tied to the disease. Workers in chemical plants, dye facilities, and rubber manufacturing carry elevated risk, as do people with long-term exposure to motor vehicle exhaust and certain industrial pollutants.
Symptoms to Recognize
The most common first sign is blood in the urine. Sometimes this is obvious, turning urine bright red or cola-colored, but in many cases the urine looks completely normal and the blood is only found on a lab test. Other symptoms include urinating more frequently than usual, pain or burning during urination, and back pain. These symptoms overlap with urinary tract infections and other benign conditions, which is why they’re easy to dismiss at first, but persistent or unexplained blood in the urine always warrants investigation.
How It’s Diagnosed
Diagnosis typically involves three tools used together. A CT urogram provides detailed imaging of the entire urinary tract, highlighting tumors or abnormalities. Urine cytology examines a urine sample under a microscope, looking for abnormal cells shed from the lining. The most definitive step is cystoscopy, where a thin camera is inserted through the urethra to directly visualize the bladder wall. If a suspicious growth is found, a tissue sample is taken during the same procedure for biopsy.
Low-Grade vs. High-Grade Tumors
Once a biopsy confirms the diagnosis, the tumor is classified as either low-grade or high-grade, a distinction that shapes treatment decisions and outlook. Low-grade tumors have cells that still look relatively organized and similar to normal urothelial tissue. Under the microscope, the nuclei are round and uniform, cell division is infrequent, and the protective umbrella cells on the surface are usually still present. These tumors tend to grow slowly and are less likely to invade deeper tissue.
High-grade tumors are a different picture. The cells lose their orderly arrangement, become varied in size and shape, and divide rapidly. The umbrella cell layer is often gone entirely. These tumors are far more likely to grow into the muscular wall of the bladder and to spread to other parts of the body. The grade matters at least as much as the size of the tumor when doctors assess how aggressive treatment needs to be.
Staging and What It Means for Outlook
Staging describes how far the cancer has spread. Localized disease, where the cancer is confined to the lining or the organ where it started, has a five-year relative survival rate of about 71%. Once it reaches nearby lymph nodes or surrounding tissue (regional stage), that drops to roughly 37%. If the cancer has spread to distant organs such as the lungs, liver, or bones, the five-year survival rate falls to about 7.5%. These are population-level averages from the SEER database, covering cases diagnosed between 2000 and 2021. Individual outcomes vary based on tumor grade, overall health, and response to treatment.
Treatment for Early-Stage Disease
Most transitional cell carcinomas are caught while still non-muscle invasive, meaning they haven’t grown past the inner lining into the bladder’s muscular wall. The initial treatment is a procedure called transurethral resection, where the tumor is scraped or cut away through a scope inserted via the urethra, with no external incision.
For high-risk non-muscle invasive tumors, the standard next step is a treatment delivered directly into the bladder. A weakened form of tuberculosis bacteria (BCG) is instilled through a catheter once a week for six weeks. This triggers a strong immune response inside the bladder that targets any remaining cancer cells. If that initial course goes well, maintenance treatments of three weekly sessions are recommended at intervals over the following three years.
In a study of 200 patients receiving this therapy, 91% completed the full six-week induction course. After a median follow-up of about three years, the one-year disease-free survival rate was 72% and the five-year rate was 41%. The five-year overall survival rate was 87%. Side effects occurred in about 18% of patients, most commonly urinary tract infections and blood in the urine. Only 9% had to stop treatment, with severe infection being the most common reason.
Treatment for Advanced Disease
When the cancer has invaded the bladder muscle, surgical removal of the bladder (with reconstruction of the urinary tract) is often recommended. Chemotherapy is typically given before or after surgery to target any cells that may have spread beyond the bladder.
For metastatic disease, platinum-based chemotherapy has long been the standard first-line treatment. In recent years, immunotherapy drugs that help the immune system recognize and attack cancer cells have changed the landscape. These checkpoint inhibitors work by blocking signals that cancer cells use to hide from immune detection. Several are now approved for patients whose cancer has progressed after chemotherapy, or for those who can’t tolerate chemotherapy in the first place. Response rates and duration of response tend to be better with immunotherapy than with older second-line options, and some patients experience long-lasting remissions.
Why Long-Term Monitoring Is Essential
Transitional cell carcinoma has one of the highest recurrence rates of any cancer. Even after successful treatment, new tumors can develop anywhere along the urothelial lining, sometimes years later. Surveillance schedules are intensive: cystoscopy and urine cytology are typically performed every three to six months during the first year, then every six to twelve months up to five years. For high-risk patients, annual monitoring continues beyond five years, sometimes indefinitely. Imaging of the upper urinary tract is included at regular intervals as well, since new cancers can appear in the ureters or kidneys even if the original tumor was in the bladder.
This rigorous follow-up schedule is one of the reasons bladder cancer is among the most expensive cancers to treat on a per-patient basis. But it’s also what allows recurrences to be caught early, when they’re still treatable with minimally invasive approaches rather than major surgery.